Glow-in-the-Dark dye could help surgeons spot hidden prostate cancer
NCT ID NCT05946603
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study tested a fluorescent dye called IS-002 that makes prostate cancer cells glow under special lights during robotic surgery. Fifty-nine men with prostate cancer received the dye before surgery, and surgeons used a special camera to see the glowing areas. The goal was to see if this helps remove all cancer and reduce leftover cancer cells at the surgical edges.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
IS-002 (a fluorescent dye)
What this could lead to
If successful, this could help surgeons remove prostate cancer more completely during robotic surgery, potentially lowering the chance of leftover cancer cells.
What could go wrong
This is a small, early feasibility study (59 people) and the dye may not reliably highlight all cancer tissue. It is not a treatment itself, only a visual aid.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Johns Hopkins
Baltimore, Maryland, 21287, United States
-
MSKCC
New York, New York, 10065, United States
-
Mayo Clinic
Rochester, Minnesota, 55905, United States
-
UCSF
San Francisco, California, 94158, United States